Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Hold for Biogen (BIIB) This Week

2018-02-16 investorplace
Biogen (BIIB) remains a Hold this week based on the latest relative pricing of its shares and SEC filings. Biogen Inc's (NASDAQ:BIIB) current Hold recommendation is grounded on an analytical score that is below average, a ranking in the company's sector group that is in the middle third, a ranking in its industry group that is in the middle third-below average, and a numerical calculation of risk/reward that is better than average. (50-0)

Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat

2018-02-16 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) reported adjusted earnings of 61 cents per share in the fourth quarter of 2017, which missed the Zacks Consensus Estimate of $1.09. However, the bottom line significantly increased from the year-ago figure of 5 cents. (97-0)

Top Analyst Upgrades and Downgrades: Alarm.com, Biogen, Blue Apron, Cisco, Lowe’s, Pandora, Waste Management and More

2018-02-16 247wallst
This week has been a wild ride, and stocks were looking for direction based on more inflationary concerns after the import prices were hotter than expected. The bull market is now just three weeks shy of being nine years old. No trend can last forever, but the one that keeps proving to be right is that investors have been rewarded handily buying the pullbacks. Now investors still have to decide how they want to be positioned for 2018 and beyond. (177-1)

FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments

2018-02-16 zacks
The FDA has proposed new guidelines, which are aimed at lowering the clinical study goals of Alzheimer’s disease drugs for treating earlier-stage patients who have not yet displayed functional disability or clinical abnormality. This strategy, part of FDA’s ongoing efforts to expand access to safe and effective treatment options for many serious conditions, suggests that the agency may be open to an accelerated approval process for such drugs. (67-0)

US FDA looks to pave way for earlier-stage Alzheimer's drugs - Channel NewsAsia

2018-02-16 channelnewsasia
U.S. regulators have proposed lowering the bar for clinical trial success for experimental Alzheimer's drugs to better align with the current emphasis on the need to treat people when they are in the earliest stages of the brain-wasting disease. (50-0)

U.S. FDA looks to pave way for earlier-stage Alzheimer's drugs

2018-02-15 reuters
Feb 15 (Reuters) - U.S. regulators have proposed lowering the bar for clinical trial success for experimental Alzheimer’s drugs to better align with the current emphasis on the need to treat people when they are in the earliest stages of the brain-wasting disease. (50-0)

Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates

2018-02-15 zacks
Alkermes plc (ALKS - Free Report) reported adjusted earnings of 31 cents per share in the fourth quarter of 2017, beating the Zacks Consensus Estimate of 21 cents. The bottom line also exceeded adjusted earnings of 15 cents recorded in the year-ago quarter. (99-0)

7 of the Best Growth ETFs | InvestorPlace

2018-02-15 investorplace
Although stocks have recently given back some of their short-term gains, the market big picture remains within the frame of momentum, which makes for a good environment to look to growth exchange-traded funds (ETFs). (483-3)

Selling Into A Void - Athersys Moves In Ignorance

2018-02-15 seekingalpha
Athersys, a clinical-stage biotech company focusing on developing their Multistem regenerative stem cell technology, has recently seen a downward share price trend accelerate along with the greater market uncertainty since the new year. Since making highs last fall of $2.55, the shares have sunk to $1.42 as of this writing (Feb. 14th). This has come to a head as ATHX is currently plunging toward its 52-week low of $1. (90-0)

Biotech Forum Daily Digest For February 15th

2018-02-15 seekingalpha
The biotech sector has stabilized and rallied this week like the rest of the overall market after two weeks of deep declines. (71-1)

Wednesday’s Biggest Winners and Losers in the S&P 500

2018-02-15 247wallst
Wednesday was a fourth consecutive positive day for the U.S. markets, again with a rocky start just like Tuesday. All three major exchanges showed some love on Valentines Day, each returning over 1%. Crude oil was feeling the love as well and recovered handily above $60. The S&P 500 sectors were almost entirely positive. The most positive sectors were financials and technology up 2.3% and 1.9%, respectively. (51-0)

Merck (MRK) Halts Another Late Stage Study on Alzheimer's

2018-02-14 zacks
Merck & Co., Inc. (MRK - Free Report) announced that it is discontinuing another study evaluating verubecestat for the treatment of prodromal Alzheimer’s disease as its success was unlikely. (56-0)

Tracking Seth Klarman's Baupost Group Holdings - Q4 2017 Update

2018-02-14 seekingalpha
The portfolio continues to be heavily concentrated, with the top three positions accounting for one-third of the 13F portfolio. (376-7)

Drug company Innoviva settles with activist hedge fund Sarissa -sources

2018-02-13 reuters
(Reuters) - U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday. (88-1)

Major Biotechs See Rising Tide of Short Interest

2018-02-12 247wallst
The short interest data are out for the most recent settlement date, January 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. The health care sector in general has rallied since Donald Trump won the presidency, but now that the fate of the ACA is uncertain, the health care rally is called into question. (287-0)

CUSIP: 09062X103